LINC01074: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC01074

NCBI ID: G106144607

LINC01074

Other Name(s): long intergenic non-protein coding RNA 1074 | Long intergenic non-protein coding RNA 1074

LINC01074: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

LINC01074 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified in various organisms, including humans. It has a unique structure, distribution, and function, which makes it an attractive candidate for drug targeting or biomarker development. In this article, we will explore the properties of LINC01074 and its potential applications in drug discovery and personalized medicine.

Structure and Localization

LINC01074 is a 24.1 kilobase (kb) RNA molecule that contains 19 exons and 11 introns. It is primarily expressed in the brain and spinal cord, and is also found in other tissues and cells, including blood cells, heart muscle, and the liver. LINC01074 is located in the genomic region between exons 1-18 of chromosome 6 (6p) and exons 1-5 of chromosome 18 (18p).

Function

LINC01074 is involved in the regulation of various cellular processes, including cell adhesion, migration, and survival. It has been shown to play a role in the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

LINC01074 has been shown to promote the survival of cancer cells by inhibiting the programmed cell death (apoptosis) pathway. This is associated with its ability to stabilize the microtubules of the mitotic spindle, which are critical for the proper separation of the chromosomes during cell division.

In addition, LINC01074 has been shown to promote the migration of cancer cells by increasing the density of its expression in the intercellular junctions between cells. This is associated with its ability to interact with the protein scaffold, which is a structural component of the intercellular junction.

Drug Targeting

The unique properties of LINC01074 make it an attractive candidate for drug targeting. Its regulation by gene expression provides a potential target for small molecules that can modulate its expression and activity. Additionally, its expression in various tissues and cells makes it a potential biomarker for disease diagnosis and prognosis.

For example, LINC01074 has been shown to be downregulated in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. This suggests that its overexpression may contribute to the pathogenesis of these diseases. Therefore, small molecules that can increase LINC01074 expression and activity may be useful for therapeutic intervention.

Biomarker Development

The expression of LINC01074 makes it an potential biomarker for disease diagnosis and prognosis. The levels of LINC01074 have been shown to be affected by various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Therefore, its expression level can be used as a diagnostic or predictive marker for these diseases.

In addition, the regulation of LINC01074 by gene expression provides a potential target for small molecules that can modulate its expression and activity. This makes LINC01074 an attractive candidate for biomarker development and drug discovery.

Conclusion

LINC01074 is a long intergenic non-protein-coding RNA that has unique structure, distribution, and function. Its regulation by gene expression and its involvement in various cellular processes make it an attractive candidate for drug targeting and biomarker development. The potential applications of LINC01074 in drug discovery and personalized medicine are vast and continue to be explored.

Protein Name: Long Intergenic Non-protein Coding RNA 1074

The "LINC01074 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01074 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets